检索结果-南通市图书馆

维普期刊数据库

前列腺MRI的PI-RADS在26个中心检测的阳性预测值差异:腹部放射学学会前列腺疾病聚焦小组的经验

在线全文

学校读者我要写书评

暂无评论

国际医学放射学杂志 2020年第5期 609-610页

作者： A.C.Westphalen C.E.McCulloch J.M.Anaokar S.arora N.S.Barashi J.O.Barentsz 刘思睿 Departments of Radiology and Biomedical Imaging University of CaliforniaSan Francisco

摘要前列腺MRI广泛应用于指导前列腺癌病人的组织活检、病情监测和肿瘤分期。前列腺成像报告和数据系统(PI-RADS)有助于提供一种标准化的概率性方法来识别有

关键词：

乳腺癌:用具有叶酸特异性的毫微型烟肼酰胺颗粒研究叶酸受体表达的MR成像

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

国际医学放射学杂志 2010年第4期 375-376页

作者： R.Meier T.D.Henning S.Boddington S.Tavri S.arora G.Piontek 焦慧 Department of Radiology University of CaliforniaSan Francisco505 Parnassus AveSan FranciscoCA 94143-0628USA

差异的显著性。运用K-W检验在不同实验组之间比较肿瘤的信噪比,并与组织病理学结果进行相关研究。P<0.05表示差异有统计学意义。结果乳腺癌叶酸受体阳性细胞显示P1133被明显

关键词：叶酸受体靶向乳腺癌乳腺肿瘤 MR 特异性酰胺酸衍生物

Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2022年第2期10卷 374-382页

作者： Yasser Fouad Melissa Palmer Minjun Chen Arie Regev Rajarshi Banerjee Rob Myers Robert Riccio Richard Torstenson Ramy Younes Puneet Sarora Henrik Landgren Morten A.Karsdal Martin Blake David A.Shapiro Hans-Juergen Gruss Muhammad Y.Sheikh Dina Attia Steven Bollipo Alastair D.Smith Bradley Freilich Robert G.Gish Detlef Schuppan Department of Gastroenterology Hepatologyand Endemic MedicineFaculty of MedicineMinia UniversityMiniaEgypt Gan-nex/Ascletis Pharma Co Ltd BeijingChina Liver Consulting LLC New YorkNYUSA Division of Bioinformatics and Biostatis-tics National Center for Toxicological ResearchUS Food and Drug AdministrationJeffersonARUSA Eli Lilly and Company IndianapolisINUSA Perspectum Diagnostics Ltd OxfordUK Gilead Sciences Inc Foster CityCAUSA Syneos Health LLC MorrisvilleNCUSA Allergan Marlow International BuckinghamshireUKAstraZenecaCambridgeUK Boehringer Ingel-heim International GmbHIngelheimGermany Genentech IncSouth San FranciscoCAUSA AbbVie MarlowBuck-inghamshireUK Nordic Bioscience A/S HerlevDenmark Resonance Health BurswoodWAAustralia Intercept Phar-maceuticals Inc San DiegoCAUSA Fresno Clinical Research Center FresnoCAUSA Gastroenterology and Hepatology Department Beni-Suef UniversityBeni SuefEgypt Department of Gastroenterology and Endoscopy John Hunter HospitalNewcastleNSWAustralia School of Medicine and Public Health University of NewcastleNewcastleNSWAustralia Kan-sas City Research Institute Kansas CityMOUSA Division of Gastroenterology and Hepatology Loma Linda UniversityLoma LindaCAUSA Institute of Translational Immunology and Research Center for Immune Therapy University Medical CenterMainzGermany Division of Gastroenterology Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonMAUSA

Metabolic(dysfunction)-associated fatty liver disease(MAFLD)affects a third of the population and is a leading cause of liver-related *** no effective treatments exist,novel approaches to drug development are ***,outdated terminology and definitions of the disease are hampering efforts to develop new drugs and *** international consensus panel has put forth an influential proposal for the disease to be renamed from nonalcoholic fatty liver disease(NAFLD)to MAFLD,includ-ing a proposal for how the disease should be *** allies with the many stakeholders in MAFLD care―including patients,patients’advocates,clinicians,researchers,nurse and allied health groups,regional societies,and others―we are aware of the negative consequences of the NAFLD term and *** share the sense of urgency for change and will act in new ways to achieve our *** there is much work to be done to overcome clinical inertia and reverse worrisome recent trends,the MAFLD initiative provides a firm foundation to build *** provides a roadmap for moving for-ward toward more efficient care and affordable,sustainable drug and device innovation in MAFLD *** hope it will bring promising new opportunities for a brighter future for MAFLD care and improve care and outcomes for patients of one of the globe’s largest and costliest public health *** this viewpoint,we have revisited this initiative through the perspectives of drug development and regulatory science.

关键词： NAFLD MAFLD NASH Fatty liver disease Liver Fibrosis

高空间分辨力MR成像监测颈动脉粥样斑块的进展——多中心研究

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

国际医学放射学杂志 2009年第6期 577-577页

作者： L.Boussel S.arora J.Rapp B.Rutt J.Huston D.Parker 范文哲 Department of Radiology Veterans Affairs Medical Center4150 Clement StSan FranciscoCA 94121USA

目的 MRI评价160例病人颈动脉粥样斑块体积的年进展率。计算MRI影像质量良好的比率。材料与方法研究过程及内容得到各中心伦理委员会的批准。所有美国的研究中心按HIPAA要求运作各个研究阶段。所有参与者均签署知情同意书。6个研究中心共入

关键词：空间分辨力空间分辨率颈动脉粥样斑 MR 多中心研究